Identification of distinct transcriptomic signatures in human HFpEF reveals potential new signaling targets for precision therapeutics.
Supports HFpEF molecular subtyping for risk stratification; leaves open whether signatures guide precision therapy selection.
HFpEF exhibits distinctive broad transcriptomic signatures and molecular subgroupings with particular clinical features and outcomes. The data reveal new signaling targets to consider for precision therapeutics.
No takes yet. Share an insight, caveat, or question.
Hahn et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: